GLP-1 Receptor Agonist Dosing Guidelines
Introduction to GLP-1 Receptor Agonists
- The American College of Cardiology recommends starting GLP-1 receptor agonists at low doses and gradually increasing them over 4-16 weeks to minimize gastrointestinal side effects 1, 2
Semaglutide Dosing Regimens
- For subcutaneous semaglutide in type 2 diabetes, the American College of Cardiology recommends starting at 0.25 mg once weekly for 4 weeks, then increasing to 0.5 mg once weekly, and finally titrating to 1 mg once weekly (or maximally tolerated dose) for glycemic control 1, 3, 2
- For subcutaneous semaglutide in weight loss, the recommended dosing regimen is to start at 0.25 mg once weekly for 4 weeks, increase to 0.5 mg once weekly for 4 weeks, then to 1.0 mg once weekly for 4 weeks, and finally to 1.7 mg once weekly for 4 weeks, with a target maintenance dose of 2.4 mg once weekly after 16 weeks of titration 2
- The maximum dose for semaglutide in diabetes is 2 mg once weekly 4
Liraglutide and Dulaglutide Dosing
- The American College of Cardiology recommends starting liraglutide at 0.6 mg subcutaneously daily and titrating slowly to 1.8 mg daily (or maximally tolerated dose) for diabetes 1, 3
- For dulaglutide, the recommended starting dose is 0.75 mg subcutaneously once weekly, with titration to 1.5 mg once weekly for cardiovascular benefit 1, 4
Exenatide and Lixisenatide Dosing
- Exenatide once weekly is administered at 2 mg subcutaneously once weekly, with no titration required 1, 3
- Lixisenatide is started at 10 mcg subcutaneously daily and titrated to 20 mcg daily as tolerated 1, 3
Critical Dosing Principles
- Slow dose escalation is essential to minimize nausea, vomiting, and other gastrointestinal adverse effects, according to the American College of Cardiology and Diabetes Care 1, 4, 5, 2
- Clinical judgment should guide adjustments based on individual response, tolerance, and adverse effects 2
Renal Dosing Adjustments
- No dose adjustment is required for semaglutide, liraglutide, or dulaglutide in renal impairment, including end-stage renal disease, as stated by the American College of Cardiology and Diabetes Care 1, 4, 3
- Exenatide once weekly requires caution with creatinine clearance 30-59 mL/min and is not recommended below 30 mL/min 3
Drug Interactions and Precautions
- The American College of Cardiology recommends not combining GLP-1 receptor agonists with other GLP-1 receptor agonists or DPP-4 inhibitors 2
- When combined with insulin or insulin secretagogues, doses of these agents should be reduced to minimize hypoglycemia risk, according to the American College of Cardiology and Diabetes Care 1, 4, 2
Gastrointestinal Management
- Reducing meal size, limiting alcohol and carbonated drinks, and avoiding high-fat diets can help minimize GI side effects, as suggested by Anaesthesia 5
- Discontinuation is recommended if pancreatitis is suspected, and restart is not advised if confirmed, according to the American College of Cardiology, Diabetes Care, and the Journal of the American College of Cardiology 1, 4, 3
Common Pitfalls
- Rapid dose escalation should be avoided, as it significantly increases gastrointestinal intolerance, according to the American College of Cardiology, Anaesthesia, and Praxis Medical Insights 1, 5, 2
- Monitoring for diabetic retinopathy progression is crucial in high-risk patients on semaglutide, as stated by Diabetes Care 4
- Sick-day planning and discontinuation 3-4 days before scheduled surgery are recommended to avoid complications, according to Diabetes Care 4
- Weight regain occurs after discontinuation, indicating the need for long-term therapy for sustained weight management, as noted by Praxis Medical Insights 2